Avelumab Combo Falls Short in Advanced Ovarian Cancer

March 20, 2019 7:00 pm

By Ian Ingram

But showed promise in PD-L1-positive group.

Adding avelumab (Bavencio) to pegylated liposomal doxorubicin (PLD) failed to improve survival outcomes for patients with platinum-resistant or refractory ovarian cancer in a phase III trial reported here.

In the intent-to-treat … Read more

Avelumab Fails to Extend PFS in Ovarian Cancer

January 2, 2019 5:00 pm

A randomized phase 3 trial designed to evaluate avelumab for women with previously untreated advanced ovarian cancer failed to achieve its primary endpoint of PFS.

The JAVELIN Ovarian 100 study has been terminated based on the finding, reported as part … Read more

Merck, Pfizer’s Bavencio Misses Ovarian Cancer Trial Endpoints

November 26, 2018 7:45 pm

By Selina McKee

A late-stage study testing Merck KGaA and Pfizer’s PD-L1 antibody Bavencio has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.

The drug was being tested as monotherapy and in combination with … Read more